Blog, Anti Cancer

Effective Way To Treat Cancer And How To Cope Up With The Side Effects Of The Medications

IMATIKAST 400

Introduction

Cancer has always been a disease that has led to a huge number of deaths. There are various kinds of cancer, out of which some are treatable while others are not. Medical science professionals are still struggling to find medications to finish cancer once and for all, although it looks like a long road.

Blood cancer and types

The other name of blood cancer is Leukemia and it is a disease that affects the blood-forming tissues and the ability of the immune system to fight back. Its growth varies from person to person, and the symptoms include fatigue, weight loss, frequent infections, and easy bleeding or bruising. Apart from medications, at a later and aggressive stage chemotherapy and even stem-cell transplant is carried out.

Medication and its side effects

The drug that is usually prescribed for Blood Cancer is IMATINIB 400 MG. It is known to treat chronic myeloid leukemia and Acute lymphocytic leukemia (2 kinds of blood cancer) and gastrointestinal stromal tumors. It is taken only after being prescribed by the doctor. It was invented in the late 1990s by Ciba-Geigy in a team. Some of the side effects are:

  • Nausea
  • Vomiting
  • Diarrhea
  • Loss of appetite
  • Rashes
  • Reduced blood cell count
  • Muscle cramp

Other brands

Many brands have started the production of this tablet such as IMATIKAST 400. These medications are very much effective just like the original medication. IMATIKAST 400 is a successful medication that is available at affordable prices. Doctors also prefer IMATIKAST 400 over other new brands that are in the market. The brand of IMATIKAST 400 is different than the generic IMATINIB 400, whose originator brand is GLIVEK, yet is favored by a several patients as well as medical practitioners.

Source: 1mg.com/drugs/imatinib-400-tablet-14358

Source: https://en.wikipedia.org/wiki/Imatinib

Leave a Reply

Your email address will not be published. Required fields are marked *